Fatigue is one of the most common symptoms in multiple sclerosis (MS), with a major impact
on patients' quality of life. Currently, treatment proceeds by trial and error with limited …

The review focuses on the clinical diagnostic utility of transcranial magnetic stimulation
(TMS). The central motor conduction time (CMCT) is a sensitive method to detect …

The greatest unmet need in multiple sclerosis (MS) are treatments that delay, prevent or
reverse progression. One of the most tractable strategies to achieve this is to therapeutically …

Innovative pro-regenerative treatment strategies for progressive multiple sclerosis (PMS),
combining neuroprotection and immunomodulation, represent an unmet need. Neural …

Background 'Encephalomyelitis disseminata'(multiple sclerosis) and myalgic
encephalomyelitis/chronic fatigue syndrome (ME/CFS) are both classified as diseases of the …

In this comprehensive, clinically directed, reference for the diagnosis and treatment of
persons with spinal cord injury and related disorders, editors of the two leading texts on …

Multiple sclerosis (MS) is a chronic autoimmune demyelinating and neurodegenerative
disease of the central nervous system with a wide variety of clinical phenotypes. In spite of …

Abstract Background Evoked potentials (EPs) are a measure of the conductivity of the
central nervous system. They are used to monitor disease progression of multiple sclerosis …

Evoked potentials (EP) characterize signal conduction in selected tracts of the central
nervous system in a quantifiable way. Since alteration of signal conduction is the main …

FTY720 (fingolimod) is an oral sphingosine 1-phosphate (S1P) receptor modulator under
development for the treatment of multiple sclerosis (MS). To elucidate its effects in the central …